Results 191 to 200 of about 908,554 (203)

Pineal region high-grade neuroepithelial tumors with NTRK fusions map to the novel methylation class “diffuse high-grade glioma, IDH-wild type, subtype E”

Acta Neuropathologica
F. Costa, João Víctor Alves de Castro, Yuri Merlotti Gomes, L. Kulikowski, B. Wolff, L. Gregianin, Cristovam Scapulatempo Neto, O. Al Dalahmah, Peter D. Canoll, Jeffrey N. Bruce, Kenneth J Aldape, Zied Abdullaev, M. Nasrallah, Cherish Alex-Wele, Scott M. Palisoul, George Zanazzi, Madhumala K. Sadanandappa   +16 more
semanticscholar   +1 more source

Entrectinib bei NTRK-Fusion-positiven Tumoren

Im Focus Onkologie, 2018
openaire   +2 more sources

173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2

Annals of Oncology, 2022
J. Lu, C.M. Blakely, M. Barve, C.H. Chung, S.N. Waqar, X. Hu, J-P. Delord, M.J. Krzakowski, K. Yonemori, D.T. Chen, D. Klingbiel, S. Heinzmann, C. Le Tourneau   +12 more
openaire   +1 more source

BPI21-006: Timing of NTRK Gene Fusion Testing and Treatment Modifications Following NTRK+ Status Among U.S. Oncologists Treating NTRK+ Patients

Journal of the National Comprehensive Cancer Network, 2021
Landon Z. Marshall, Andrew J. Klink, Abhishek Kavati, Ruth Antoine, Sibyl Anderson, Bruce Feinberg   +5 more
openaire   +1 more source

NTRK Fusions and Trk Proteins: What are They and How to Test for Them.

Human Pathology, 2021
L. Weiss, V. Funari
semanticscholar   +1 more source

Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology

Drugs, 2021
K. Rohrberg, U. Lassen
semanticscholar   +1 more source

Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.

Human Pathology, 2022
Zi-cheng Zhang, J. Pang, Longyun Chen, Jingci Chen, Junjie Li, Hangqi Liu, Jing Wang, Huanwen Wu, Z. Liang   +8 more
semanticscholar   +1 more source

A Comparison of the Histopathologic Features of Thyroid Carcinomas with NTRK Fusions to Those with Other Malignant Fusions.

Human Pathology
I. Tondi Resta, Anfal Rind, K. Montone, V. Livolsi, Z. Baloch   +4 more
semanticscholar   +1 more source

NTRK gene fusions: a rough diamond ready to sparkle

The Lancet Oncology, 2020
openaire   +2 more sources

Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

The Lancet Oncology, 2020
openaire   +3 more sources